Does Insurance Cover GLP-1s for Weight Loss?

“Will my insurance pay for it?” is often the first practical question after someone learns that a GLP-1 medication like Wegovy or Zepbound could help with weight loss. The honest answer is that it depends on three things: the type of coverage you have, the specific plan you are in, and why the medicine is being prescribed.

This guide walks through each kind of US coverage, from employer plans and ACA Marketplace plans to Medicare and Medicaid, using the latest public data from KFF, CMS, Medicare.gov and HealthCare.gov. It also explains prior authorization, how appeals work, and what to ask your insurer before you start.

Coverage rules change often. Figures below were reviewed on October 17, 2026. Always confirm with your own plan. This article is general information, not medical, legal or financial advice.

The short answer

Insurance coverage of GLP-1 medications for weight loss is still the exception rather than the rule in the US, although it has been growing in some places and shrinking in others.

• Employer plans: Some cover them, usually with conditions. In KFF’s 2025 Employer Health Benefits Survey, 19% of firms with 200 or more workers that offer health benefits covered GLP-1s used primarily for weight loss. Among the largest firms (5,000 or more workers), it was 43%, up from 28% in 2024.
• ACA Marketplace plans: Most do not cover GLP-1s for weight loss.
• Medicare: Federal law prohibits Part D plans from covering drugs used only for weight loss. A temporary program, the Medicare GLP-1 Bridge, offers certain GLP-1s for a $50 monthly copay to eligible Part D enrollees from July 1, 2026 through December 31, 2027.
• Medicaid: Covering weight-loss drugs is optional for states. KFF counted 13 states covering GLP-1s for obesity under fee-for-service as of January 2026.

Coverage of the same medicines for type 2 diabetes is much more common. That difference explains a lot of the confusion people run into.

As the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) puts it, “some, but not all, insurance plans cover medications that treat overweight and obesity.” Its advice is simple: contact your insurer and ask.

Why the reason for the prescription matters so much

Insurers usually decide coverage based on the diagnosis and the FDA-approved use, not just the molecule. Semaglutide is sold as Ozempic for type 2 diabetes and as Wegovy for weight management and other uses. Tirzepatide is sold as Mounjaro for type 2 diabetes and as Zepbound for weight management and obstructive sleep apnea. (Our guides to Wegovy vs Ozempic and Zepbound vs Mounjaro explain the differences in detail.)

Many plan documents exclude “weight-loss drugs” as a category. That exclusion may not apply when the same drug is prescribed for a different approved use. For example:

• Type 2 diabetes: Diabetes-labeled GLP-1s are widely covered.
• Cardiovascular risk reduction: Wegovy gained an approval in March 2024 to reduce the risk of serious heart problems in adults with established heart disease and obesity or overweight. KFF notes that Medicare Part D plans can cover it for that use.
• Obstructive sleep apnea: Zepbound gained an approval in December 2024 for moderate to severe obstructive sleep apnea in adults with obesity. Medicare Part D and Medicaid can cover it for that use too.

This does not mean a diagnosis can be stretched to fit the coverage. Your clinician must prescribe based on your actual medical situation, and the plan will usually ask for records that support it. It does mean you should tell your clinician about every relevant condition, such as diagnosed sleep apnea or a past heart attack, because it can change which coverage rules apply.

Employer-sponsored insurance

Job-based insurance is where weight-loss coverage is most common, but it is far from universal. In KFF’s 2025 survey, 55% of workers were covered by a health plan offered by their employer.

What the data show

KFF’s 2025 Employer Health Benefits Survey asked firms whether their largest health plan covered GLP-1s “when used primarily for weight loss.” Among firms that offer health benefits:

Firm size	Share covering GLP-1s for weight loss (2025)
200 to 999 workers	16%
1,000 to 4,999 workers	30%
5,000 or more workers	43% (up from 28% in 2024)
All firms with 200+ workers	19%

The same survey found that 34% of firms covering these drugs for weight loss require enrollees to meet with a dietitian, case manager or therapist, or join a lifestyle program, to keep coverage. Among large firms that do not cover them, only 1% said they were “very likely” to start in the next 12 months, and 67% said they were not likely to.

Cost pressure is a big reason. Among the largest firms that cover GLP-1s for weight loss, 59% said use was higher than expected and 66% said it had a “significant” effect on their prescription drug spending. KFF also reported that some employers have stopped covering these medicines for weight loss. Its 2026 survey is scheduled for release on October 22, 2026, so newer figures are coming.

Other 2026 employer surveys, summarized by healthinsurance.org, point the same way: roughly a third of employers in one survey cover GLP-1s for both diabetes and weight loss, and 5% to 10% of employers that now cover GLP-1s for weight loss plan to drop that coverage in 2027.

Self-funded vs fully insured plans

How your employer buys coverage matters:

• Self-funded plans, where the employer pays claims directly, cover most people with job-based insurance. The employer designs the drug benefit, so coverage of weight-loss drugs depends on that specific employer’s choices.
• Fully insured plans, bought from an insurance company, depend on the products the insurer offers. In the small-group market, plans must include at least the benefits in their state’s “essential health benefits” benchmark, and most of those benchmarks do not include weight-loss drugs.

On social media, people describe exactly this patchwork: one person’s plan covers a GLP-1 with a small copay, while another person with the same insurer brand finds the drug has been dropped from the formulary by their pharmacy benefit manager (the company that runs the drug benefit). Both experiences can be true, because each employer and each benefit manager sets its own list.

ACA Marketplace (individual) plans

If you buy your own insurance through HealthCare.gov or a state exchange, weight-loss coverage is rare.

According to healthinsurance.org, a 2024 KFF analysis found that most Marketplace plans covered GLP-1s for diabetes, but only 1% covered Saxenda or Wegovy for weight loss, and none covered Zepbound for weight loss. A separate analysis of 2026 plans that it cites found only 26 of about 300 carriers nationwide offering any coverage of GLP-1s for obesity, often limited to people with a BMI of 40 or higher.

Part of the reason is the essential health benefits benchmark each state sets. Healthinsurance.org reports that North Dakota is the only state whose benchmark specifically includes GLP-1 coverage for weight loss (for severe obesity), starting in 2025. Several states have passed or are debating laws on weight-loss drug coverage for state employee plans, Medicaid or private plans, so check your state’s current rules during open enrollment.

If coverage matters to you, compare plan formularies (the list of covered drugs) carefully when you shop. A plan’s summary may not mention GLP-1s at all; the formulary and the plan’s prior authorization criteria will.

Medicare

Medicare is where the rules changed most in 2026.

What regular Part D covers

From the start of the Part D drug benefit, Medicare has been prohibited by law from covering medicines when used specifically for weight loss. KFF explains that people on Medicare can get GLP-1s covered by Part D only for a medically accepted FDA-approved use other than obesity, such as type 2 diabetes, cardiovascular risk reduction or sleep apnea.

The Medicare GLP-1 Bridge

To expand access, CMS created a temporary nationwide demonstration called the Medicare GLP-1 Bridge. It operates separately from your regular Part D plan. Here is what Medicare.gov and CMS say about it:

• Dates: July 1, 2026 through December 31, 2027. (It was originally set to end in December 2026; CMS extended it.)
• Covered drugs: Wegovy (injection or tablet), Foundayo (tablet), and Zepbound KwikPen only. Single-dose Zepbound vials and pens are not included.
• Cost: a $50 copayment for a one-month supply (28 or 30 days, depending on the drug).
• Who can use it: people with Medicare drug coverage, including stand-alone drug plans, many Medicare Advantage plans with drug coverage, Special Needs Plans and employer or union group plans.

You must be 18 or older and, when you start therapy, meet one of these:

BMI	Plus at least one of these conditions
35 or higher	None required
30 or higher	Heart failure with preserved ejection fraction, uncontrolled high blood pressure, or chronic kidney disease stage 3a or higher
27 or higher	Prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease

You are not eligible for the Bridge if your Part D plan already covers a GLP-1 for you, or if you have type 2 diabetes, moderate to severe sleep apnea or fatty liver disease. Medicare says your regular Part D plan might cover a GLP-1 for those conditions instead.

Your clinician must send the prescription, complete a prior authorization when requested, and certify that you are using the medicine as part of a lifestyle program focused on diet and exercise. Medicare says an approved prior authorization stays valid, including for refills and dose changes, through December 31, 2027, unless you switch GLP-1s.

Notice that these criteria are stricter than the FDA labels, which generally allow use at a BMI of 30, or 27 with at least one weight-related condition. Our guide to who qualifies for GLP-1 weight-loss treatment compares them side by side.

The fine print on the $50 copay

Because the Bridge sits outside Part D, Medicare.gov notes that the $50 copay:

• does not count toward your Part D deductible or yearly out-of-pocket limit ($2,100 in 2026, rising to $2,400 in 2027, according to KFF),
• cannot be lowered by Extra Help, the program that helps people with limited income pay Part D costs, and
• cannot be spread across months with the Medicare Prescription Payment Plan.

KFF points out that this may make the Bridge harder to use for people with low incomes. KFF also reports that manufacturers agreed to a net price of $245 per month’s supply under the program.

What happens after 2027?

That is genuinely uncertain. CMS had planned a longer program, the BALANCE Model, to bring GLP-1 coverage for obesity into Part D plans from 2027. In April 2026, CMS announced it would not move forward with BALANCE in Medicare in 2027 and extended the Bridge instead. KFF notes there is no clear path for Medicare coverage of GLP-1s for obesity after 2027 unless CMS extends the Bridge again or launches another option. If you start treatment through the Bridge, talk with your clinician about a plan in case coverage changes.

Medicaid

Medicaid coverage depends heavily on where you live.

Under federal law, state Medicaid programs must cover nearly all FDA-approved drugs for their approved uses, but weight-loss drugs are one of a few categories states may exclude. KFF explains the result:

• Coverage of GLP-1s for type 2 diabetes, cardiovascular risk reduction (Wegovy) and moderate to severe obstructive sleep apnea in adults with obesity (Zepbound) is required.
• Coverage for obesity alone is optional for each state.
• Children and teens under 21 can get coverage when it is deemed medically necessary under Medicaid’s EPSDT benefit (Early and Periodic Screening, Diagnostic and Treatment).

As of January 2026, KFF counted 13 state Medicaid programs covering GLP-1s for obesity under fee-for-service, down from 16 in October 2025. California, New Hampshire, Pennsylvania and South Carolina ended coverage for obesity, citing budget pressure. North Carolina dropped coverage in October 2025 and reinstated it in December 2025. Healthinsurance.org reports further changes, including a BMI threshold of 40 in Michigan and an end to weight-loss coverage in Rhode Island starting October 2026. Where states do cover these drugs, prior authorization is typical.

The Medicaid side of the BALANCE Model is going ahead. States can join on a rolling basis from May 2026 through January 1, 2027. Participating states use standard coverage criteria negotiated by CMS and the manufacturers, and they may offer broader coverage but not stricter criteria. CMS notes that the model “will not guarantee coverage for any individual,” because it depends on whether your state joins. Your state Medicaid agency or managed care plan can tell you what applies to you.

Out-of-pocket costs for Medicaid enrollees are limited to nominal amounts under federal law, so when Medicaid does cover a GLP-1, the cost to you is usually low.

Prior authorization, step therapy and other hurdles

Even when a plan covers GLP-1s for weight loss, you usually cannot just fill the prescription. Expect some combination of:

• Prior authorization (PA): your clinician submits documentation, typically your BMI and weight-related conditions, before the plan pays.
• BMI thresholds: some plans use the FDA label criteria; others set a higher bar.
• Lifestyle program requirements: proof of participation in a diet, exercise, dietitian or coaching program, before or during treatment.
• Step therapy: a requirement to try a less expensive medicine first.
• Preferred products: a plan may cover one GLP-1 but not another, so your clinician may need to choose the covered option.
• Renewals and limits: periodic re-approval, sometimes tied to how much weight you have lost, or a cap on how long coverage lasts.

Our step-by-step guide on how to get a GLP-1 prescription covers what to bring to the visit and who usually handles the prior authorization paperwork.

What to ask your insurer before you start

A 10-minute call can save weeks. Have your member ID ready, and ask for answers in writing when possible.

1. Does my plan cover Wegovy, Zepbound, Foundayo or other GLP-1s for weight management? Which are preferred?
2. Is prior authorization required, and what are the exact criteria (BMI, conditions, program participation)?
3. Is there step therapy? Which medicines must be tried first, and for how long?
4. What will I pay: a flat copay or a percentage (coinsurance)? Does the drug count toward my deductible?
5. How often must the authorization be renewed, and what is needed to renew it?
6. Is there a time limit or a weight or BMI point at which coverage stops? Is maintenance treatment covered?
7. Do I have to use a specific pharmacy or mail-order service?
8. If my clinician prescribes for a different approved use, such as sleep apnea or heart disease, do different rules apply?

Write down the date, the representative’s name and what they told you. Share the criteria with your clinician’s office so the first prior authorization request is complete.

If your claim is denied: how appeals work

A denial is not always the final word. For most private health plans, federal rules described on HealthCare.gov give you two levels of appeal.

Internal appeal

• Your plan must tell you in writing why it denied coverage, generally within 15 days for a prior authorization request, or within 72 hours for urgent cases.
• You generally have 180 days (6 months) from the denial to file an internal appeal.
• Include the plan’s forms (or a letter with your name, claim number and member ID) and any supporting information, such as a letter from your clinician explaining medical necessity.
• For a service you have not received yet, the internal appeal must be decided within 30 days.

External review

• If the plan still says no, you can ask an independent third party to review the decision. You generally have 4 months after the final denial to request it.
• A standard external review must be decided within 45 days; an expedited review within 72 hours when the situation is urgent.
• The plan is legally required to accept the reviewer’s decision. The cost is either nothing or no more than $25, depending on who runs the review.
• Your state’s Consumer Assistance Program or Department of Insurance can help you file.

When an appeal is likely to help, and when it is not

Appeals work best when the denial involves medical judgment or missing paperwork: the plan said the drug was “not medically necessary,” the BMI was not documented, or the record did not show a required program. Fixing the documentation often matters more than the letter itself.

Appeals are much harder when the plan excludes weight-loss drugs as a benefit. If your plan simply does not cover that category, an appeal may not change the outcome, though it is still worth asking whether a different approved use applies to you. Medicare and Medicaid have their own appeal processes; your plan or state agency can explain them.

If insurance won’t pay: other routes

If coverage is not available, you still have options to discuss with your clinician:

• Manufacturer self-pay programs. Brand-name makers now sell some GLP-1s directly to cash-paying patients at prices well below list. Our guide to semaglutide cost without insurance breaks down current cash prices, and the GLP-1 cost guide compares options.
• Savings cards for commercially insured patients. These can lower copays when your plan covers the drug, but they generally exclude Medicare, Medicaid and other government coverage.
• Patient assistance and state programs. Medicare.gov suggests checking manufacturer help, state drug-cost programs, mail-order pricing and drug-price comparison sites. It also warns that discount cards and cash purchases do not count toward Medicare deductibles or out-of-pocket limits.
• Open enrollment. If coverage is important to you, compare formularies when you choose a plan for next year, including your employer’s options.
• Telehealth programs. Some online clinics help with prior authorization; others work only with cash pay. See how telehealth weight-loss programs work for what to ask.

Be wary of the cheapest-looking route. Compounded or “research-only” versions of these drugs are not FDA-approved. The FDA has received reports of adverse events, some requiring hospitalization, that may be linked to dosing errors with compounded semaglutide, and it warns that illegally marketed versions sold online may be counterfeit or contain the wrong amount of active ingredient. A low price is not a safety guarantee.

Common myths about GLP-1 coverage

“If my plan covers Ozempic, it covers Wegovy.” Not necessarily. Plans often cover the diabetes product and exclude the weight-management product, even though both contain semaglutide.

“Medicare now covers weight-loss drugs.” Only partly, and only for now. Regular Part D still cannot cover drugs used only for weight loss. The Bridge is a temporary demonstration with its own criteria, running through December 31, 2027.

“Meeting the FDA label criteria guarantees coverage.” No. Plans set their own rules, and some, including the Medicare Bridge, are stricter than the label.

“Once approved, always approved.” Many authorizations expire and must be renewed, and plans can change formularies from year to year.

How this affects your plan

Coverage is a moving target. Large employers have expanded weight-loss coverage while some smaller employers, Marketplace carriers and state Medicaid programs have pulled back, and Medicare’s temporary access has a set end date. KFF polling found that 56% of GLP-1 users said the drugs were difficult to afford, which shows how much the coverage question matters.

The practical approach is the same for everyone:

1. Find out what your plan covers and why, in writing.
2. Give your clinician the exact criteria so the first request is complete.
3. Know your appeal rights and deadlines.
4. Make a backup plan with your clinician in case coverage changes, rather than stopping suddenly or rationing doses on your own.

Remember that GLP-1 medicines are typically used long term, and weight often returns when they stop (our guide to how GLP-1s work for weight loss explains why). Planning for how you will pay over the long run, not just the first month, is part of making a good decision.

The bottom line

Insurance coverage for GLP-1s used for weight loss in the US depends on your plan type, your plan’s specific rules and the reason for the prescription. Some large employers cover these drugs with prior authorization and program requirements; most Marketplace plans do not. Medicare’s regular Part D still excludes weight-loss drugs, but the temporary Medicare GLP-1 Bridge offers Wegovy, the Zepbound KwikPen and Foundayo for $50 a month to eligible enrollees through 2027. Medicaid coverage depends on your state. Call your insurer with a short list of questions, share the answers with your clinician, and use your appeal rights if a denial looks like a paperwork or medical-necessity issue.

For prices and payment options, continue with our GLP-1 costs hub. For the clinical side, start with what a GLP-1 medication is and which GLP-1s are FDA-approved for weight loss, or browse the GLP-1 Guide.

Medical disclaimer: Weightomics publishes general health information for education only. It is not a substitute for professional medical, legal or financial advice. Never start, stop or change a medication without talking to a licensed clinician. Coverage rules cited were reviewed October 17, 2026 and may change without notice; confirm details with your plan, Medicare or your state Medicaid program.